Physician profile
David Yu
NPI 1346212354
$8,446.01
in general payments reported to CMS, 2019-2025
32 companies · $2,085 in 2025
The $2,085 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $648 · 2021: $1,240 · 2022: $1,274 · 2023: $910 · 2024: $794 · 2025: $2,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,642.03 | 2019-2025 | Rocklatan, Clareon, Centurion |
| Abbvie INC. | $884.15 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Allergan, INC. | $867.22 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $830.53 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $657.56 | 2019-2023 | |
| Sight Sciences, INC. | $405.58 | 2021-2025 | Omni Surgical System, Tearcare System |
| Glaukos Corporation | $346.66 | 2019-2024 | Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $345.01 | 2022-2025 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $281.04 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $277.60 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $267.79 | 2019-2021 | |
| Nova Eye, INC. | $234.31 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $192.98 | 2019-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Horizon Therapeutics Plc | $181.76 | 2022-2023 | Tepezza |
| Shire North American Group INC | $149.12 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $135.82 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $103.36 | 2024-2025 | Miebo, Vyzulta, Envista Aspire Toric Iol |
| New World Medical,INC. | $95.52 | 2019 | |
| Ocular Therapeutix, INC. | $75.85 | 2022-2025 | Dextenza |
| Thea Pharma INC. | $69.60 | 2024-2025 | Iyuzeh |
| Genentech USA, INC. | $50.08 | 2022 | |
| Dompe US, INC. | $48.67 | 2023-2024 | Oxervate |
| Ivantis, INC | $47.07 | 2021 | |
| Akorn Operating Company LLC | $43.56 | 2021 | |
| Akorn, INC. | $39.87 | 2019-2020 | |
| Harrow Eye, LLC | $39.18 | 2025 | Vevye |
| Carl Zeiss Meditec, INC. | $31.60 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.14 | 2025 | Purified Cortrophin Gel |
| Eyepoint US, INC. | $24.96 | 2019 | |
| Rxsight INC | $18.09 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Kala Pharmaceuticals, INC. | $17.99 | 2019 | |
| Biotissue Holdings INC. | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.